Indivior Announces Q4 and FY 2021 Results

Rhea-AI Summary

Indivior PLC (LON: INDV) reported its financial results for the fiscal year ending December 31, 2021, showcasing its commitment to addressing substance use disorders and mental illnesses. The company aims to enhance access to evidence-based treatments globally. Indivior's product pipeline focuses on opioid use disorder treatments and related chronic conditions. The earnings release, investor presentation, and additional materials are available online, with a webcast presentation scheduled for today at 8:00 AM US EST.

Positive

• Indivior is dedicated to expanding access to evidence-based treatments for substance use disorders.
• The company has a strong pipeline targeting opioid use disorder and related chronic conditions.

Negative

• None.

SLOUGH, England and RICHMOND, Va., Feb. 16, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending December 31, 2021. The earnings release, investor presentation and webcast are available at www.indivior.com.

• The earnings press release can be found at https://www.indivior.com/en/media/press-releases
• The investor presentation can be found at https://www.indivior.com/investors

The earnings release, investor presentation and webcast are available at www.indivior.com. 

Indivior will also host a webcast presentation today at 8:00 AM US EST / 13:00 GMT.

The webcast event link is https://edge.media-server.com/mmc/p/8tao6fad

Participants may also access the presentation telephonically:

US participants 1-646-741-3167

International participants +44 (0) 2071-928338

Please reference confirmation ID 8268632. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-q4-and-fy-2021-results-301483233.html

SOURCE Indivior

FAQ

What were Indivior's financial results for FY 2021?

Indivior announced its financial results for the fiscal year ending December 31, 2021, highlighting its ongoing commitment to addressing substance use disorders.

What is Indivior's plan for opioid use disorder treatments?

Indivior aims to expand its pipeline with products targeting opioid use disorder and other related chronic conditions.

Where can I access Indivior's investor presentation?

Indivior's investor presentation is available at their official website under the investors section.

When is Indivior's webcast presentation?

Indivior's webcast presentation is scheduled for today at 8:00 AM US EST.